Virtual Library

Start Your Search

C. Park



Author of

  • +

    P1.06 - Poster Session/ Screening and Early Detection (ID 218)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Screening and Early Detection
    • Presentations: 1
    • +

      P1.06-029 - Serum Glutathione Peroxidase 3 as a Biomarker of Postoperative Relapse in Patients with Lung Cancer (ID 892)

      09:30 - 09:30  |  Author(s): C. Park

      • Abstract
      • Slides

      Background:
      Glutathione peroxidase 3 (GPx3) which is an extracellular secretory protein is down regulated in patients with early stage lung cancer. We examined the usefulness of serum GPx3 as a biomarker for monitoring of relapse after surgery.

      Methods:
      We prospectively collected serial serum samples at baseline, 3 months (3m), 6 months (6m), and 12 months (12m) after operation from the patients who underwent surgery during the year 2013. GPx3 levels were measured three times per sample using the enzyme-linked immunosorbent assay, and the mean values were analyzed by repeated measure analysis of variance.

      Results:
      A total of 126 (73 adenocarcinoma, 31 squamous cell carcinoma, 22 others) patients were analyzed in this study. Median age of patients was 66 years old (range, 39-80) and 19 (15.4%) out of 123 lung cancer patients were confirmed relapse during the follow-up period of 2 years. In squamous cell carcinoma, the changes of mean serum GPx3 were significantly different between relapse (baseline: 13.3 ± 1.1 μg/mL, 3m: 17.1 ± 4.6 μg/mL, 6m: 14.8 ± 2.7 μg/mL, 12m: 17.9 ± 1.7 μg/mL) and control group (baseline: 10.8 ± 2.3 μg/mL, 3m: 13.4 ± 3.4 μg/mL, 6m: 12.4 ± 2.6 μg/mL, 12m: 13.5 ± 4.7 μg/mL, p=0.043). The changes of mean serum GPx3 levels were not different between two groups in all histology (p=0.258) and adenocarcinoma (p=0.701).

      Conclusion:
      Postoperative serum GPx3 levels were significantly elevated only in relapsed squamous cell histology, not in adenocarcinoma. More large scaled validation studies are warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P2.04-089 - Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Tumor DNA During EGFR-Tyrosine Kinase Inhibitor Treatment (ID 575)

      09:30 - 09:30  |  Author(s): C. Park

      • Abstract
      • Slides

      Background:
      Epidermal growth factor receptor (EGFR) mutations are predictive marker of EGFR-tyrosine kinase inhibitor (TKI) therapy. We compared the sensitivity of EGFR mutation detection techniques between tumor tissue and peripheral blood sample in patients with EGFR-TKI treatment.

      Methods:
      We collected plasma and serum sample before EGFR-TKI and after acquired resistance in 11 patients with EGFR mutations (5 cases of 19 deletion and 5 cases of L858R) from paraffin-embedded tissues using PNAClamp[TM]EGFR Mutation Detection kit. DNA extraction from plasma and serum was performed using the QIAamp MinElute virus spin kit. EGFR mutation analysis for blood was done by pyrosequencing and PANAMutyper[TM]R EGFR kit. The degree of agreement was evaluated by Cohen's kappa value.

      Results:
      The median EGFR-TKI duration of total 11 (7 male, 4 female) cases was 6 months (range 4-24). The sensitivity of plasma EGFR mutations were 33.3% in pyrosequencing. The sensitivities of PANAMutyper[TM]R were 72.7% in plasma and 45.5% in serum sample. The degree of agreements between tissue and blood sample were better in plasma PANAMutyper[TM]R (k=0.429, p=0.033) and serum PANAMutyper[TM]R (k=0.290, p=0.026) than plasma pyrosequencing (k=0.194, p=0.087). After the development of acquired resistance, plasma EGFR mutations were still detected in 4 cases by PANAMutyper[TM]R. One of them showed 19 deletion and T790M mutation at the same time.

      Conclusion:
      The sensitivity and the strength of agreement of PANAMutyper[TM]R test were better than pyrosequencing. So this technique can be useful to detect EGFR mutation in peripheral blood.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.